Avanish Vellanki, Cofounder and CEO at Rain Therapeutics, discusses the recent initiation of the phase 3 MANTRA trial of milademetan versus trabectedin in patients with dedifferentiated liposarcoma.
Liposarcoma is a rare cancer originating from fat cells located in the soft tissues of the body. It is a malignant cancer that can spread to other parts of the body. Well-differentiated liposarcoma is less aggressive and tends to present as a large painless mass found in deeper tissues. Dedifferentiated liposarcoma is more aggressive, arising from well-differentiated liposarcoma, and is usually found in tissue behind the abdominal area or the extremities. Well-differentiated and dedifferentiated liposarcoma are the most frequent subtypes of liposarcoma and share common genomic abnormalities, predominately MDM2 gene amplification.
As Mr. Vellanki explains, MANTRA is a recently initiated phase 3 study comparing milademetan (an MDM2 inhibitor) to trabectedin (standard of care) in patients with dedifferentiated liposarcoma. The trial will enroll patients with unresectable or metastatic dedifferentiated liposarcoma with or without a well-differentiated liposarcoma component. To be eligible for enrollment, patients will need to have progressed on 1 or more previous systemic therapies, including at least 1 anthracycline-based therapy. According to Mr. Vellanki, the company expects to enroll 160 participants to the trial. The primary end point of the trial is progression-free survival (PFS). Key secondary endpoints include overall survival, investigator-assessed PFS, objective response rate, duration of response, disease control rate, safety, and patient-reported outcomes.
To learn more about dedifferentiated liposarcoma and other rare cancers, visit checkrare.com/diseases/cancers/
